ATE269711T1 - Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv - Google Patents

Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv

Info

Publication number
ATE269711T1
ATE269711T1 AT97917971T AT97917971T ATE269711T1 AT E269711 T1 ATE269711 T1 AT E269711T1 AT 97917971 T AT97917971 T AT 97917971T AT 97917971 T AT97917971 T AT 97917971T AT E269711 T1 ATE269711 T1 AT E269711T1
Authority
AT
Austria
Prior art keywords
hsv
pathogen
formulation
prevention
including hiv
Prior art date
Application number
AT97917971T
Other languages
English (en)
Inventor
Michel G Bergeron
Andre Desormeaux
Michel Tremblay
Original Assignee
Infectio Recherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectio Recherche Inc filed Critical Infectio Recherche Inc
Application granted granted Critical
Publication of ATE269711T1 publication Critical patent/ATE269711T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
AT97917971T 1996-05-09 1997-05-09 Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv ATE269711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1710696P 1996-05-09 1996-05-09
PCT/CA1997/000319 WO1997042962A1 (en) 1996-05-09 1997-05-09 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv

Publications (1)

Publication Number Publication Date
ATE269711T1 true ATE269711T1 (de) 2004-07-15

Family

ID=21780760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917971T ATE269711T1 (de) 1996-05-09 1997-05-09 Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv

Country Status (17)

Country Link
US (1) US6068851A (de)
EP (1) EP0930886B1 (de)
JP (1) JP2000510836A (de)
KR (1) KR20000010834A (de)
CN (1) CN1177594C (de)
AP (1) AP1406A (de)
AT (1) ATE269711T1 (de)
AU (1) AU723081B2 (de)
BR (1) BR9709228A (de)
CA (1) CA2258811C (de)
DE (1) DE69729646T2 (de)
HK (1) HK1019560A1 (de)
IL (1) IL126804A0 (de)
NO (1) NO985148L (de)
NZ (1) NZ332578A (de)
OA (1) OA11096A (de)
WO (1) WO1997042962A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
US6482805B2 (en) * 1998-03-25 2002-11-19 Parker Hughes Institute AZT derivatives exhibiting spermicidal and anti-viral activity
US6191120B1 (en) * 1998-03-25 2001-02-20 Wayne Hughes Institute Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2′,3′-dideoxy-uridines and their pharamaceutical compositions
ES2284250T3 (es) * 1998-04-21 2007-11-01 Infectio Recherche Inc. Formulaciones para la prevencion o el tratamiento de enfermedades que afectan a la membrana mucosa o la piel, o para la prevencion del embarazo.
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
IL151649A0 (en) * 2000-03-07 2003-04-10 Rush Presbyterian St Luke Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
JP2004536017A (ja) * 2000-06-23 2004-12-02 メルク　エンド　カムパニー　インコーポレーテッド カチオン性界面活性剤を含有するポリヌクレオチドワクチンのアジュバント及び製剤とその使用方法
US7465295B2 (en) 2000-10-20 2008-12-16 Bergeron Michel G Applicator for the delivery of topical formulations into mucosal cavities
AU2003205227A1 (en) * 2002-01-18 2003-09-02 Emory University Phthalocyanine and porphyrazine pharmaceutical compositions
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
AU2003275069A1 (en) * 2002-09-20 2004-04-08 La Jolla Biosciences Compositions and methods for preventing infection
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
US20050014719A1 (en) * 2003-06-24 2005-01-20 Khan Adil A. Method of controlling viral outbreak
US20050095283A1 (en) * 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
AU2005231738A1 (en) * 2004-03-26 2005-10-20 Katz, David F. Mr Bioresponsive polymer system for delivery of microbicides
BRPI0510004A (pt) * 2004-04-20 2007-09-18 Univ Chicago artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
JP2006111585A (ja) * 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
WO2006054589A1 (ja) * 2004-11-18 2006-05-26 Terumo Kabushiki Kaisha 医薬組成物、製剤および組み合わせ製剤
US20060127459A1 (en) * 2004-12-15 2006-06-15 Lei Huang Urogenital infection inhibition
KR100775315B1 (ko) 2005-08-03 2007-11-08 벤자민 원 박 성병과 에이즈예방용 윤활젤 조성물
US20080078408A1 (en) * 2005-04-18 2008-04-03 Park Benjamin W Urethral condoms and liquid female condoms
WO2006112632A1 (en) * 2005-04-18 2006-10-26 Benjamin Won Park Urethral condoms and liquid femidoms
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
US20070134747A1 (en) * 2005-12-14 2007-06-14 Kimberly-Clark Worldwide, Inc. Detection of secreted lipase proteins from Candida species
MX2009011938A (es) * 2007-05-04 2009-11-13 Procter & Gamble Composiciones antimicrobianas, productos y metodos de uso.
CN101557802B (zh) * 2007-12-03 2013-10-30 特里逻辑药业有限责任公司 自凝固的可生物蚀解的屏障植入物
WO2010045479A1 (en) * 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
DE102009034771B4 (de) * 2009-07-25 2011-09-01 Martin Schmitt Hautschutzmittel
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011084610A1 (en) * 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes for preventing the spread of hiv
US10039709B2 (en) * 2010-06-04 2018-08-07 Trilogic Pharma Llc Bioadhesive compositions for epithelial drug delivery
AU2013256008B2 (en) * 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
WO2014210156A1 (en) 2013-06-25 2014-12-31 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
EP3484485A1 (de) 2016-07-12 2019-05-22 Centre National De La Recherche Scientifique Zusammensetzungen zur schleimhautheilung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IT1240354B (it) * 1990-03-30 1993-12-07 Poli Ind Chimica Spa Formulazioni liposomiali di farmaci antimicotici,antibatterici e/o antantiflogistici per applicazione locale e vaginale
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1250748B (it) * 1991-08-02 1995-04-21 Poli Ind Chimica Spa Formulazioni utili per il trattamento della secchezza vaginale
IT1255460B (it) * 1992-07-28 1995-11-02 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
EP0789565A4 (de) * 1993-10-15 1999-03-24 Jess G Thoene Prävention der hiv-infektion

Also Published As

Publication number Publication date
KR20000010834A (ko) 2000-02-25
EP0930886A1 (de) 1999-07-28
IL126804A0 (en) 1999-08-17
US6068851A (en) 2000-05-30
WO1997042962A1 (en) 1997-11-20
AP1406A (en) 2005-05-04
AU2629997A (en) 1997-12-05
CA2258811C (en) 2003-11-25
NO985148D0 (no) 1998-11-04
EP0930886B1 (de) 2004-06-23
AP9801382A0 (en) 1998-12-31
CA2258811A1 (en) 1997-11-20
OA11096A (en) 2003-03-13
BR9709228A (pt) 1999-08-10
CN1177594C (zh) 2004-12-01
AU723081B2 (en) 2000-08-17
NZ332578A (en) 2000-06-23
DE69729646D1 (de) 2004-07-29
CN1218403A (zh) 1999-06-02
DE69729646T2 (de) 2005-07-07
HK1019560A1 (en) 2000-02-18
JP2000510836A (ja) 2000-08-22
NO985148L (no) 1999-01-08

Similar Documents

Publication Publication Date Title
ATE269711T1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69426506D1 (de) Vorhof-Defibrillator zur Nachweisung von T-Wellen und zur Feststellung von Zwischenzeiten von Kardiovertierung
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69428734T2 (de) Vollständig substituierte cyclopholysiloxane und ihre Verwendung zur Herstellung von Organosilziumpolymeren
ATE312597T1 (de) Verwendung von nanodispersionen in pharmazeutischen endformulierungen
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE69815866D1 (de) Verwendung von shogaolen und gingerolen zur herstellung von deodoranzien
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE59504541D1 (de) Steuer- und Kontrollverfahren zur Anwendung in der Weiterverarbeitung von Druckereierzeugnissen
DE59101214D1 (de) Verwendung der Ascorbinsäure zur Zubereitung von Arzneimitteln zur Anwendung im Genitalbereich.
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE69615714D1 (de) Phosphat-zusammensetzung und ihre verwendung
DE69803925D1 (de) Methode zur kalt-sterilisation von öfen des tunnel-typs im pharmazeutischen bereich und öfen zur anwendung dieser methode
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DE69016606D1 (de) Zusammensetzungen zur kontrollierten Haftverminderung und ihre Verwendung.
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
DE69830259D1 (de) Gewebeschutzmittel und der Gebrauch desselben
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties